Knight Cancer clinicians at Tuality/OHSU Cancer Center are the first in Oregon to offer a treatment option that will improve outcomes for patients with bladder cancer who cannot tolerate surgery or...
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...
Cancer researchers have identified key factors in the surroundings of tumor cells that it may be possible to target to improve outcomes for patients with HER2-positive breast cancer. Co-principal...
Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients,...
Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...